Please assess the completion status of the following clinical trial:

Trial Title: TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir (TMC114/r) in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented HIV-1 infection~* Screening plasma HIV-1 RNA \>= 5000 copies/mL~* Patients qualify for treatment initiation based on the investigator's assessments and/or according to treatment guidelines~* Patients who can comply with the protocol requirements~* General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.~Exclusion Criteria:~* Presence of any currently active AIDS defining illness or receiving treatment for primary HIV infection~* Life expectancy of less than 6 months~* Previous or current use of antiretroviral medications (ARVs) for the treatment of HIV-infection or hepatitis B infection with anti-HIV activity~* Female -patients who are pregnant or breast-feeding, or are of childbearing potential without use of effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period~* -patients with a grade 3 or 4 laboratory abnormality as defined by DAIDS grading, or a calculated creatinine clearance (CLCr) \< 70 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
- 001 (Type: ACTIVE_COMPARATOR): LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).